MiNK Therapeutics Statistics
Share Statistics
MiNK Therapeutics has 39.55M shares outstanding. The number of shares has increased by 14.54% in one year.
| Shares Outstanding | 39.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13.86% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.92M |
| Failed to Deliver (FTD) Shares | 1.86K |
| FTD / Avg. Volume | 4.78% |
Short Selling Information
The latest short interest is 51.73K, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 51.73K |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 1.1 |
Valuation Ratios
The PE ratio is -1.64 and the forward PE ratio is -1.86.
| PE Ratio | -1.64 |
| Forward PE | -1.86 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -2.04 |
| P/FCF Ratio | -2.32 |
| PEG Ratio | n/a |
Enterprise Valuation
MiNK Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of 0.
| Current Ratio | 0.32 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 1.24% and return on capital (ROIC) is 126.95%.
| Return on Equity (ROE) | 1.24% |
| Return on Assets (ROA) | -4.93% |
| Return on Capital (ROIC) | 126.95% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -724.45K |
| Employee Count | 31 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -37.25% in the last 52 weeks. The beta is 0.05, so MiNK Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.05 |
| 52-Week Price Change | -37.25% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 29.07 |
| Average Volume (20 Days) | 39.01K |
Income Statement
In the last 12 months, MiNK Therapeutics had revenue of $0 and earned -$22.46M in profits. Earnings per share was $-0.65.
| Revenue | 0 |
| Gross Profit | -204.62K |
| Operating Income | -22.92M |
| Net Income | -22.46M |
| EBITDA | -22.25M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
The company has $3.37M in cash and $0 in debt, giving a net cash position of $3.37M.
| Cash & Cash Equivalents | 3.37M |
| Total Debt | 0 |
| Net Cash | 3.37M |
| Retained Earnings | -133.40M |
| Total Assets | 7.37M |
| Working Capital | 6.57B |
Cash Flow
In the last 12 months, operating cash flow was -$15.76M and capital expenditures -$73.56K, giving a free cash flow of -$15.84M.
| Operating Cash Flow | -15.76M |
| Capital Expenditures | -73.56K |
| Free Cash Flow | -15.84M |
| FCF Per Share | -0.46 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
INKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -101.56% |
| FCF Yield | -62.56% |
Analyst Forecast
The average price target for INKT is $6.5, which is 915.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 915.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -27428.09 |
| Piotroski F-Score | 1 |